Financhill
Sell
12

RAFA Quote, Financials, Valuation and Earnings

Last price:
$0.0700
Seasonality move :
183.05%
Day range:
$0.0863 - $0.0863
52-week range:
$0.0330 - $0.1790
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
100
Avg. volume:
21.2K
1-year change:
-14.57%
Market cap:
$7.2M
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
RAFA
Rafarma Pharmaceuticals
-- -- -- -- --
CGTX
Cognition Therapeutics
-- -$0.12 -- -57.41% $5.40
COCP
Cocrystal Pharma
-- -$0.51 -- -0.94% $8.33
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
PDSB
PDS Biotechnology
-- -$0.25 -- -28.33% $7.50
TNXP
Tonix Pharmaceuticals Holding
$2.6M -$3.09 20.02% -99.46% $60.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
RAFA
Rafarma Pharmaceuticals
$0.0863 -- $7.2M -- $0.00 0% --
CGTX
Cognition Therapeutics
$0.35 $5.40 $22M -- $0.00 0% --
COCP
Cocrystal Pharma
$1.57 $8.33 $16M -- $0.00 0% 7.93x
NBY
NovaBay Pharmaceuticals
$0.58 $0.85 $3.4M -- $0.00 0% 0.16x
PDSB
PDS Biotechnology
$1.16 $7.50 $52.7M -- $0.00 0% --
TNXP
Tonix Pharmaceuticals Holding
$19.14 $60.00 $123.2M -- $0.00 0% 2.41x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
RAFA
Rafarma Pharmaceuticals
-- -3.885 -- --
CGTX
Cognition Therapeutics
-- -2.549 -- --
COCP
Cocrystal Pharma
-- 3.309 -- --
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PDSB
PDS Biotechnology
-- 0.123 -- --
TNXP
Tonix Pharmaceuticals Holding
5.09% -9.056 5.18% 5.84x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
RAFA
Rafarma Pharmaceuticals
-- -- -- -- -- --
CGTX
Cognition Therapeutics
-- -$7.7M -- -- -- -$8.4M
COCP
Cocrystal Pharma
-- -$5M -- -- -- -$5.1M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
PDSB
PDS Biotechnology
-- -$10.2M -- -- -- -$8M
TNXP
Tonix Pharmaceuticals Holding
$1.4M -$21.6M -127.14% -138.47% -834.78% -$14.6M

Rafarma Pharmaceuticals vs. Competitors

  • Which has Higher Returns RAFA or CGTX?

    Cognition Therapeutics has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat Cognition Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    CGTX
    Cognition Therapeutics
    -- -$0.17 --
  • What do Analysts Say About RAFA or CGTX?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Cognition Therapeutics has an analysts' consensus of $5.40 which suggests that it could grow by 1422.41%. Given that Cognition Therapeutics has higher upside potential than Rafarma Pharmaceuticals, analysts believe Cognition Therapeutics is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    CGTX
    Cognition Therapeutics
    4 0 0
  • Is RAFA or CGTX More Risky?

    Rafarma Pharmaceuticals has a beta of 1.185, which suggesting that the stock is 18.453% more volatile than S&P 500. In comparison Cognition Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock RAFA or CGTX?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cognition Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Cognition Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or CGTX?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Cognition Therapeutics quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than Cognition Therapeutics's net income of -$7.8M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Cognition Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus -- for Cognition Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    CGTX
    Cognition Therapeutics
    -- -- -- -$7.8M
  • Which has Higher Returns RAFA or COCP?

    Cocrystal Pharma has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat Cocrystal Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    COCP
    Cocrystal Pharma
    -- -$0.49 --
  • What do Analysts Say About RAFA or COCP?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Cocrystal Pharma has an analysts' consensus of $8.33 which suggests that it could grow by 430.79%. Given that Cocrystal Pharma has higher upside potential than Rafarma Pharmaceuticals, analysts believe Cocrystal Pharma is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    COCP
    Cocrystal Pharma
    1 0 0
  • Is RAFA or COCP More Risky?

    Rafarma Pharmaceuticals has a beta of 1.185, which suggesting that the stock is 18.453% more volatile than S&P 500. In comparison Cocrystal Pharma has a beta of 2.127, suggesting its more volatile than the S&P 500 by 112.692%.

  • Which is a Better Dividend Stock RAFA or COCP?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Cocrystal Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or COCP?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Cocrystal Pharma quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than Cocrystal Pharma's net income of -$4.9M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Cocrystal Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 7.93x for Cocrystal Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    COCP
    Cocrystal Pharma
    7.93x -- -- -$4.9M
  • Which has Higher Returns RAFA or NBY?

    NovaBay Pharmaceuticals has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of -49.65%. Rafarma Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About RAFA or NBY?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that NovaBay Pharmaceuticals has higher upside potential than Rafarma Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is RAFA or NBY More Risky?

    Rafarma Pharmaceuticals has a beta of 1.185, which suggesting that the stock is 18.453% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock RAFA or NBY?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or NBY?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rafarma Pharmaceuticals's net income of -- is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns RAFA or PDSB?

    PDS Biotechnology has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of --. Rafarma Pharmaceuticals's return on equity of -- beat PDS Biotechnology's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    PDSB
    PDS Biotechnology
    -- -$0.29 --
  • What do Analysts Say About RAFA or PDSB?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand PDS Biotechnology has an analysts' consensus of $7.50 which suggests that it could grow by 546.55%. Given that PDS Biotechnology has higher upside potential than Rafarma Pharmaceuticals, analysts believe PDS Biotechnology is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    PDSB
    PDS Biotechnology
    2 0 0
  • Is RAFA or PDSB More Risky?

    Rafarma Pharmaceuticals has a beta of 1.185, which suggesting that the stock is 18.453% more volatile than S&P 500. In comparison PDS Biotechnology has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.741%.

  • Which is a Better Dividend Stock RAFA or PDSB?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. PDS Biotechnology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or PDSB?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than PDS Biotechnology quarterly revenues of --. Rafarma Pharmaceuticals's net income of -- is lower than PDS Biotechnology's net income of -$10.7M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while PDS Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus -- for PDS Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    PDSB
    PDS Biotechnology
    -- -- -- -$10.7M
  • Which has Higher Returns RAFA or TNXP?

    Tonix Pharmaceuticals Holding has a net margin of -- compared to Rafarma Pharmaceuticals's net margin of -856.24%. Rafarma Pharmaceuticals's return on equity of -- beat Tonix Pharmaceuticals Holding's return on equity of -138.47%.

    Company Gross Margin Earnings Per Share Invested Capital
    RAFA
    Rafarma Pharmaceuticals
    -- -- --
    TNXP
    Tonix Pharmaceuticals Holding
    54.18% -$9.77 $147M
  • What do Analysts Say About RAFA or TNXP?

    Rafarma Pharmaceuticals has a consensus price target of --, signalling downside risk potential of --. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $60.00 which suggests that it could grow by 213.48%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Rafarma Pharmaceuticals, analysts believe Tonix Pharmaceuticals Holding is more attractive than Rafarma Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    RAFA
    Rafarma Pharmaceuticals
    0 0 0
    TNXP
    Tonix Pharmaceuticals Holding
    1 0 0
  • Is RAFA or TNXP More Risky?

    Rafarma Pharmaceuticals has a beta of 1.185, which suggesting that the stock is 18.453% more volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 1.627, suggesting its more volatile than the S&P 500 by 62.658%.

  • Which is a Better Dividend Stock RAFA or TNXP?

    Rafarma Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rafarma Pharmaceuticals pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios RAFA or TNXP?

    Rafarma Pharmaceuticals quarterly revenues are --, which are smaller than Tonix Pharmaceuticals Holding quarterly revenues of $2.6M. Rafarma Pharmaceuticals's net income of -- is lower than Tonix Pharmaceuticals Holding's net income of -$22.1M. Notably, Rafarma Pharmaceuticals's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rafarma Pharmaceuticals is -- versus 2.41x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    RAFA
    Rafarma Pharmaceuticals
    -- -- -- --
    TNXP
    Tonix Pharmaceuticals Holding
    2.41x -- $2.6M -$22.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is BYD a Threat To Tesla Shareholders?
Is BYD a Threat To Tesla Shareholders?

BYD (OTC:BYDDY) has rocketed to the top of China’s booming…

CVX Vs XOM Stock, Which Energy Play Is Best?
CVX Vs XOM Stock, Which Energy Play Is Best?

Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…

Is it Safe to Invest in Google With OpenAI Threats?
Is it Safe to Invest in Google With OpenAI Threats?

For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
60
RGC alert for May 8

Regencell Bioscience Holdings [RGC] is up 17.9% over the past day.

Buy
92
TPB alert for May 8

Turning Point Brands [TPB] is down 7.41% over the past day.

Buy
74
LIVN alert for May 8

LivaNova PLC [LIVN] is up 1.31% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock